We described the establishment of the conjunctival SCC cell line PeCa-UkHb-01. The aim of this work was to develop a model for further in vitro studies on conjunctival SCCs. Although nonmalignant conjunctival cell lines have been generated,
25,26 establishment of cell lines from this carcinoma, to our knowledge, has not been reported so far.
To isolate the cells, we used a tissue sample from a conjunctival tumor histologically confirmed to be a conjunctival SCC. The protocol applied to generate the cell line corresponded to protocols reported for the establishment of cell lines from other SCCs.
17 The pure epithelial cell line obtained by selective trypsinization was subjected to further characterizations.
PeCa-UkHb-01 cells were maintained in culture for at least 60 passages, thus demonstrating that they are capable of long-term culture as compared with regular conjunctival cells. Primary cultures of conjunctival cells were reported to be able to remain in culture for up to 1 month without passaging and, depending on the culture conditions, capable of being passaged up to five times.
26,27 There are established conjunctival epithelial cell lines from nonmalignant tissue which are able to be cultivated over extended periods of time. One of them, IOBA-NHC, spontaneously immortalized in culture; others were immortalized by transfection
28 or contained chromosomes of cancer cells.
25 However, PeCa-UkHb-01 cells were not manipulated to gain the ability of unlimited growth.
The calculated doubling time of 34.7 hours was in line with respective times from head and neck SCCs, which had doubling times between 17 and 240 hours with a median of 26.5 hours.
29
Recently, cell lines from other tissues which have been used for extensive molecular genetic or immunohistological analyses were proven to be derived not from the original tumor, but were contaminated by other cell lines or even cells of handling technicians.
30 Therefore, STR analyses were performed to prove the origin of PeCa-UkHb-01 from the donor. Despite minor differences between blood DNA and cell line DNA, especially loss of heterozygosity in the cell line, the data seemed to confirm the origin of the cells. For instance, in passages numbers 18 and 25 no STRs from the Y chromosome were detected. The differences between the STR results of the blood and cell line samples are probably explained by mutations or cross-chromosomal rearrangements. Due to the lack of tumor tissue DNA, it is not possible to say if the mutations have already occurred during tumor development or in cell culture. In the second case, it could be assumed that further mutations happened between ongoing passages, but given the almost identical STR results of passage numbers 10 and 25, this seems unlikely. To solve this open question, further experiments have to be performed in the future.
The karyotype analysis of PeCa-UkHb-01 detected abnormal chromosomal arrangements and heterogeneity between the donor's blood cells and different cells of the cell line, as well as among the cells of a particular passage (
Figs. 4,
5). A comparison of cell culture–, blood-, and tumor-samples was not possible, because the procedure to generate karyograms is not applicable on tissue samples. For karyogram generation it is necessary to perform a metaphasis arrest on proliferating cells.
In PeCa-UkHb-01 cells, mainly deletions or additions of one chromosome and the addition of an isochromosom to a newly attached chromosome were observed. These cytogenetic features are not surprising because chromosomal aberrations caused by an inherent genomic instability
31 are a common feature in many cancer cells, including SCC cell lines.
17,32–34 The detected loss of the Y chromosome in PeCa-UkHb-01 is a process that also occurs frequently in SCC cell lines. Hunter et al.
35 have published that 8 of 13 (62%) SSC cell lines from esophagus of male donors have lost their Y chromosome. Loss of the Y chromosome was also observed in regular cells from elderly male donors.
36,37 In general, the results of STR analysis and karyotype determination are in line. The heterogeneity of PeCa-UkHb-01 might limit the ability to use them in in vitro studies emphasizing the need to generate PeCa-UkHb-01 cultures with a homogenous chromosomal arrangement. A lot of different SCC cell lines available are heterogeneous in their chromosomal arrangement.
32 They originated from a tumor, but for a really homogenous cell line a single cell must be used. As far as we know, only the cell lines USC-HN1 and USC-HN2 fulfill these criteria.
17,34 Recently, a study by Asnaghi et al.
38 examined DNA copy number alterations in a series of conjunctival SCCs. They detected chromosomal alterations, which are potentially important in tumor formation and growth, especially the frequent amplification of the p-arm of chromosome 8. This kind of alteration could not definitely be identified in the cell line. While chromosome 8 was found in triplicates, with possible addition of an isochromosom at the q-arm, there was no clear hint of an amplification of the p-arm. Nevertheless, because there were a number of chromosomes and fragments which could not be assigned, it cannot be ruled out that p-arm amplification took place. Further studies on the cells are needed to validate this.
The characterization of PeCa-UkHb-01 by means of immunologic staining and gene expression analysis by real-time PCR was performed to determine the phenotype of the new cell line. The cell line A431 used as comparison in real-time PCR experiments is a model cell line for cancer research.
22 The results of the comparison displayed some similarities and differences. The epithelial markers K3, K15, K19, and EpCAM were detected by immunocytochemistry and PCR analysis (
Figs. 6,
9). The expression of EpCAM was initially detected as a dominant surface antigen in human colon carcinoma tissue and is highly expressed in various human carcinomas.
39 The cytokeratin K3 is a characteristic epithelial marker of the corneal surface, while K15 is a popular marker of corneal epithelial progenitor cells.
40,41 Cytokeratin K19 is a marker of conjunctival epithelium and corneal epithelial progenitor cells.
41,42 The almost 1000-fold increased expression of K19 in our cell line compared with the epidermoid derived A431 cells is likely due to the conjunctival origin of the cells. The expression of K19 was confirmed in immunocytochemistry. The staining and expression pattern for K19 and EpCAM was comparable in early and late passages with no differences found, indicating no relevant phenotypic changes in the course of the cultivation.
ABCG2 is expressed in cancer cells and associated with resistance of the tumor against chemotherapeutics, making it a potential target for anticancer therapies.
43 The marker ΔNp63α is an isoform of the p63 protein, which is involved in cancer cell metabolism.
44 Ye et al.,
45 for example, demonstrated the value of ΔNp63α for cellular proliferation in esophageal squamous cell carcinoma cell lines by silencing its expression. Both markers were detected by PCR as well as immunocytochemistry. It should be noted that, unlike the real-time PCR assay, the monoclonal antibody used to detect p63 was not isoform specific for ΔNp63α. The staining for p63 revealed a less intense staining of this marker in late passages compared with early passages. It remains unclear if this observation is caused merely by coincidence or by a real decrease in expression, which might occur after extended cell culture. With the isoform ΔNp63α used in the semiquantitative real-time PCR no expression differences were noted. Nevertheless, it is noteworthy that all examined passages showed expression of ABCG2 and p63. Polymerase chain reaction data showed a comparable expression of the markers in PeCa-UkHb-01 and A431. It was lower for DNp63a in PeCa-UkHb-01 early and late, and higher for ABCG2 in PeCa-UkHb-01 early, but lower for PeCa-UkHb-01 late; the differences did not seem to be significant.
Real-time PCR further revealed the expression of OCT4, SOX2, and c-MYC in PeCa-UkHb-01. These proteins have been found in neoplastic cancers and ocular surface epithelial progenitor cells.
41,46 In cancer cell lines, an artificially increased OCT4 expression demonstrated the ability of cells to initiate tumors.
47 SOX2, a key gene that controls transcriptional networks required for pluripotency, has a prognostic value for the progression and clinical outcome in other SCC types.
46,48,49 Increased amplification of SOX2 was reported to be a common incidence in SCCs.
46 The biomarker cMYC was demonstrated to be amplified more frequently in advanced stages of esophageal SCC.
50 The expression analysis revealed that c-MYC expression in A431 was comparable with PeCa-UkHb-01 in early passages. However, the one sample of the late passage of PeCa-UkHb-01 displayed a higher expression. OCT4 and SOX2 were expressed at higher levels. Immunocytochemical analysis of cell culture confirmed the expression of OCT4 and SOX2 in PeCa-UkHb-01 cells. The staining for SOX2 revealed a strong cytoplasmic staining for the protein (
Fig. 8). As a transcription factor, SOX2 was reported to be predominantly localized in the nucleus, but in case of cultivated cells depending on the used antibodies or staining conditions, a positive-staining signal could also occur in the cytoplasm.
51
The noted discrepancies in the biomarker expression patterns of early and late passages of PeCa-UkHb-01 can be indicative for modifications gained during cultivation or the result of the chromosomal heterogeneity. The significance of these findings in PeCa-UkHb-01 has yet to be examined.
The results of the characterization demonstrate that PeCa-UkHb-01 cells display functional features of SCC cells. They are able to be maintained in culture for long periods of time and display chromosomal aberrations and heterogeneity common for tumor cells.
Finally, the expression of tumor associated biomarkers by our cells, which are also present in the model SCC cell line A431 as well as in other SCCs, underline that cellular mechanisms working in SCCs may be also active in PeCa-UkHb-01. In the future, the PeCa-UkHb-01 cell line might be a useful experimental tool to develop new therapeutic modalities in ophthalmic oncology.